Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Neoadjuvant chemotherapy for breast cancer allows individual tumor response to be assessed depending on molecular subtype, and to judge the impact of response to therapy on recurrence-free survival (RFS). The multicenter I-SPY 1 TRIAL evaluated patients with ≥3 cm tumors by using early imaging and m...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Esserman, Laura J., Berry, Donald A., Cheang, Maggie C. U., Yau, Christina, Perou, Charles M., Carey, Lisa, DeMichele, Angela, Gray, Joe W., Conway-Dorsey, Kathleen, Lenburg, Marc E., Buxton, Meredith B., Davis, Sarah E., van’t Veer, Laura J., Hudis, Clifford, Chin, Koei, Wolf, Denise, Krontiras, Helen, Montgomery, Leslie, Tripathy, Debu, Lehman, Constance, Liu, Minetta C., Olopade, Olufunmilayo I., Rugo, Hope S., Carpenter, John T., Livasy, Chad, Dressler, Lynn, Chhieng, David, Singh, Baljit, Mies, Carolyn, Rabban, Joseph, Chen, Yunni-Yi, Giri, Dilip, Au, Alfred, Hylton, Nola
Format: Artigo
Langue:Inglês
Publié: Springer US 2011
Sujets:
Clinical Trial
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3332388/
https://ncbi.nlm.nih.gov/pubmed/22198468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1895-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires